16th Nov 2015 06:43
LONDON (Alliance News) - AstraZeneca PLC has called on the UK government to develop a new model for incentivising investment in antibiotics and warned on the "terrible human cost" of the rise in drug-resistant infections, the Financial Times reported.
In a letter to the FT, the pharmaceuticals company joined others in the life sciences sector in pushing the UK to pursue a new system rather than waiting for an international agreement to be sealed.
John Rex, the head of anti-infective drug development for AstraZeneca, said a new payment model is needed which will reward companies' investment but without encouraging the over-use of antibiotics.
https://next.ft.com/content/7d3fd1de-8a08-11e5-90de-f44762bf9896
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca